STOCK TITAN

Omnicell (OMCL) Financials

OMCL NASDAQ
Trailing 12 months to September 30, 2026
Revenue $1.2B +5.6% YoY
Net Income $44.7M +124.2% YoY
EPS (Diluted) $0.96 +123.3% YoY
Free Cash Flow $145.8M +30.8% YoY
Market Cap $1.5B as of Nov 19, 2026
Price / Sales 1.2x on $1.2B revenue, trailing 12 months to September 30, 2026
Price / Earnings 34.2x on $44.7M net income, trailing 12 months to September 30, 2026
Price / Book 1.2x on $1.3B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OMCL SEC filings page.

Omnicell Inc (OMCL) reported $1.2B in revenue over the twelve months to Sep 30, 2026, up 5.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OMCL FY2025

Revenue recovered, but cash generation and bottom-line earnings weakened while the balance sheet became less debt-heavy.

FY2025’s cash conversion mismatch is the clearest operating signal: operating cash flow was $127.3M against net income of $2.1M. Yet cash production deteriorated year over year: free cash flow fell 42.6% and operating cash flow fell 32.2%, so the gap should not be read as durable earnings strength.

The balance sheet has been materially deleveraged: long-term debt was $167.6M in FY2025 versus $569.7M in FY2023, reducing financing dependence. Total liabilities fell 15.4% in the latest year, but the current ratio was 1.4x, so improvement is more visible in solvency than in short-term liquidity.

The revenue rebound did not produce much operating leverage: gross margin was 42.5% and operating margin only 0.4%, leaving little profit after direct and operating costs. Capital spending was only 3.4% of revenue; the 42.6% FCF decline therefore points away from an investment spike and toward weaker cash generation.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 46 / 100
Financial Health Score 46/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Omnicell Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
25

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Omnicell Inc scores 25/100 on it among other operating companies.

Growth
36

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Omnicell Inc scores 36/100 on it among other operating companies.

Leverage
83

Omnicell Inc held more cash than long-term debt at the end of fiscal year 2025, with $196.5M of cash against $167.6M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Omnicell Inc scores 83/100 among other operating companies measured the same way.

Liquidity
40

Omnicell Inc held $1.43 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.43. Liquidity ranks operating companies on that ratio, and Omnicell Inc scores 40/100 among other operating companies.

Cash Flow
66

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Omnicell Inc scores 66/100 on it among other operating companies.

Returns
25

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Omnicell Inc scores 25/100 on it among other operating companies.

Altman Z-Score Grey Zone
2.24

Omnicell Inc scores 2.24, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $1.5B against total liabilities of $742.9M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
7/9

Omnicell Inc passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed
N/A

Omnicell Inc reported $2.1M of net income while generating $127.3M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$307.9M
YoY-0.9%
QoQ-1.4%
5Y CAGR+0.8%
10Y CAGR+5.7%

Omnicell Inc generated $307.9M in revenue in Q3 2026. This represents a decrease of 0.9% from the same quarter a year earlier. Against the prior quarter it is down 1.4%.

EBITDA
$33.3M
YoY+20.6%
QoQ-35.0%
5Y CAGR-6.9%
10Y CAGR+5.4%

Omnicell Inc's EBITDA was $33.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 35.0%.

Net Income
$11.0M
YoY+102.2%
QoQ-54.5%
5Y CAGR-17.7%
10Y CAGR+18.7%

Omnicell Inc reported $11.0M in net income in Q3 2026. This represents an increase of 102.2% from the same quarter a year earlier. Against the prior quarter it is down 54.5%.

EPS (Diluted)
$0.24
YoY+100.0%
QoQ-53.8%
5Y CAGR-17.0%

Omnicell Inc earned $0.24 per diluted share (EPS) in Q3 2026. This represents an increase of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 53.8%.

Cash & Balance Sheet

Free Cash Flow
$21.7M
YoY+17.1%
QoQ-63.5%
5Y CAGR-9.7%

Omnicell Inc generated $21.7M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 17.1% from the same quarter a year earlier. Against the prior quarter it is down 63.5%.

Cash & Debt
$314.9M
YoY+74.9%
QoQ+7.8%
5Y CAGR-8.1%
10Y CAGR+20.9%

Omnicell Inc held $314.9M in cash against $168.5M in long-term debt as of Q3 2026.

Shares Outstanding
46M
YoY+2.5%
QoQ+0.8%
5Y CAGR+0.9%

Omnicell Inc had 46M shares outstanding in Q3 2026. This represents an increase of 2.5% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
44.8%
YoY+1.5pp
QoQ-4.2pp
5Y change-4.7pp
10Y change-1.4pp

Omnicell Inc's gross margin was 44.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.2 percentage points.

Operating Margin
4.9%
YoY+2.2pp
QoQ-5.5pp
5Y change-5.1pp
10Y change+2.1pp

Omnicell Inc's operating margin was 4.9% in Q3 2026, reflecting core business profitability. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.5 percentage points.

Net Margin
3.6%
YoY+1.8pp
QoQ-4.2pp
5Y change-6.3pp
10Y change+2.5pp

Omnicell Inc's net profit margin was 3.6% in Q3 2026, showing the share of revenue converted to profit. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.2 percentage points.

Return on Equity
0.8%
YoY+0.4pp
QoQ-1.0pp
5Y change-1.8pp
10Y change+0.4pp

Omnicell Inc's quarterly ROE was 0.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.

Capital Allocation

R&D Spending
$22.4M
YoY-6.9%
QoQ+10.1%
5Y CAGR+2.8%
10Y CAGR+3.9%

Omnicell Inc invested $22.4M in research and development in Q3 2026. This represents a decrease of 6.9% from the same quarter a year earlier. Against the prior quarter it is up 10.1%.

Share Buybacks
$0
YoY-100.0%

Omnicell Inc repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Capital Expenditures
$11.4M
YoY+16.5%
QoQ+27.1%
5Y CAGR+10.7%

Omnicell Inc invested $11.4M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 16.5% from the same quarter a year earlier. Against the prior quarter it is up 27.1%.

OMCL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OMCL quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$307.9M-0.9%$312.2M+7.4%$309.9M+14.9%$314.0M+2.3%$310.6M+10.0%$290.6M+5.0%$269.7M+9.6%$306.9M+18.6%
Cost of Revenue$170.0M-3.5%$159.3M-2.2%$169.5M+6.8%$183.7M+11.2%$176.1M+10.0%$162.9M+0.3%$158.7M+3.4%$165.1M+7.6%
Gross Profit$137.8M+2.5%$152.9M+19.8%$140.4M+26.5%$130.3M-8.1%$134.5M+10.0%$127.7M+11.7%$110.9M+19.8%$141.8M+34.5%
R&D Expenses$22.4M-6.9%$20.3M-5.9%$21.5M+4.8%$22.6M-13.4%$24.0M+13.2%$21.6M+2.2%$20.5M-6.9%$26.0M-2.9%
SG&A Expenses$100.5M-1.7%$100.2M+2.2%$102.0M0.0%$107.4M+3.9%$102.2M+8.2%$98.0M+8.8%$102.0M+10.4%$103.3M+1.3%
Operating Income$14.9M+81.1%$32.4M+299.6%$16.9Mn/m$415K-96.7%$8.2M+25.6%$8.1M+151.9%-$11.6Mn/m$12.4Mn/m
EBITDA$33.3M+20.6%$51.2M+84.9%$35.4M+322.9%$20.2M-37.5%$27.6M+3.3%$27.7M+15.4%$8.4Mn/m$32.4Mn/m
Income Tax$4.8M+12.2%$9.5M+98.3%$5.5Mn/m$2.7M-64.9%$4.2M+41.5%$4.8M+7.9%-$2.5Mn/m$7.8Mn/m
Net Income$11.0M+102.2%$24.3M+330.7%$11.4Mn/m-$2.0M-112.8%$5.5M-36.7%$5.6M+51.0%-$7.0Mn/m$15.8Mn/m
EPS (Basic)$0.24+100.0%$0.53+341.7%$0.25n/m-$0.05-114.7%$0.12-36.8%$0.12+50.0%-$0.15n/m$0.34n/m
EPS (Diluted)$0.24+100.0%$0.52+333.3%$0.25n/m-$0.05-114.7%$0.12-36.8%$0.12+50.0%-$0.15n/m$0.34n/m
Diluted Shares (Avg)46M+1.2%46M-1.5%46M-1.4%N/A46M-1.1%47M+2.1%47M+1.9%N/A

Not reported in any period shown, so not listed: Interest Expense.

OMCL Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OMCL quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$2.1B+5.6%$2.0B-6.8%$2.0B-6.8%$2.0B-6.9%$1.9B-15.4%$2.1B-6.4%$2.2B-5.8%$2.1B-4.8%
Current Assets$784.0M+18.9%$735.4M-12.9%$722.3M-14.0%$680.1M-16.6%$659.6M-34.8%$844.8M-15.2%$839.7M-15.2%$815.5M-12.1%
Cash & Equivalents$314.9M+74.9%$292.2M-26.8%$239.2M-38.2%$196.5M-46.8%$180.1M-68.4%$399.0M-28.3%$386.8M-24.5%$369.2M-21.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$98.3M-8.5%$96.7M-8.6%$99.2M+8.8%$100.9M+13.8%$107.4M+13.0%$105.8M+13.4%$91.1M-11.9%$88.7M-19.5%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$737.1M-0.1%$737.2M-0.2%$737.3M+0.2%$737.9M+0.4%$737.9M+0.1%$738.5M+0.4%$736.0M+0.1%$734.7M-0.1%
Total Liabilities$739.6M+1.6%$707.3M-19.8%$747.5M-16.4%$742.9M-15.4%$727.7M-32.1%$881.9M-19.0%$894.4M-18.3%$877.6M-15.4%
Current Liabilities$473.7M+3.7%$447.4M-24.7%$483.0M-20.5%$476.6M-20.0%$456.6M-52.5%$594.4M+46.0%$607.5M+45.9%$595.7M+62.0%
Non-Current Liabilities$265.9M-1.9%$259.8M-9.6%$264.4M-7.8%$266.3M-5.6%$271.1M+144.8%$287.5M-57.8%$286.8M-57.7%$282.0M-57.9%
Long-Term Debt$168.5M+0.7%$168.2M+0.7%$167.9M+0.7%$167.6M+0.7%$167.3M$167.0M-70.8%$166.7M-70.8%$166.4M-70.8%
Total Equity$1.3B+7.9%$1.3B+2.2%$1.3B0.0%$1.2B-0.9%$1.2B-0.8%$1.3B+5.1%$1.3B+5.8%$1.2B+4.6%
Retained Earnings$431.6M+11.5%$420.6M+10.2%$396.3M+5.4%$384.9M+0.5%$387.0M+5.4%$381.5M+6.4%$375.9M+6.0%$382.9M+3.4%

Not reported in any period shown, so not listed: Accounts Receivable.

OMCL Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OMCL quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$33.1M+16.9%$68.3M+59.8%$54.5M+110.2%$30.4M-46.1%$28.3M+24.2%$42.8M-27.2%$25.9M-48.1%$56.3M+46.6%
Depreciation & Amortization$18.4M-5.2%$18.8M-4.1%$18.6M-7.1%$19.8M-0.8%$19.4M-4.0%$19.6M-5.8%$20.0M-5.9%$20.0M-8.1%
Stock-Based Compensation$11.4M+1.8%$12.2M+15.9%$9.5M-11.9%N/A$11.2M-3.4%$10.5M+5.0%$10.8M+24.8%N/A
Capital Expenditures$11.4M+16.5%$8.9M-24.1%$12.4M+11.3%$7.7M-15.2%$9.8M+10.0%$11.8M+23.3%$11.2M+24.7%$9.1M+0.2%
Free Cash Flow$21.7M+17.1%$59.4M+91.7%$42.1M+185.1%$22.6M-52.1%$18.5M+33.3%$31.0M-37.0%$14.8M-64.0%$47.2M+60.9%
Investing Cash Flow-$13.1Mn/m-$12.5Mn/m-$15.9Mn/m-$14.4Mn/m-$14.3Mn/m-$15.9Mn/m-$15.7Mn/m-$13.6Mn/m
Financing Cash Flow-$4.9Mn/m-$23.4Mn/m$2.4M-40.8%$9.1Mn/m-$220.0M-6289.7%-$11.5Mn/m$4.0M-66.1%-$234.4M-1885.5%
Share Buybacks$0-100.0%N/AN/A$0n/m$61.9Mn/mN/AN/A$0n/m

Not reported in any period shown, so not listed: Dividends Paid.

OMCL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OMCL quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin44.8%+1.5pp49.0%+5.0pp45.3%+4.2pp41.5%-4.7pp43.3%0.0pp43.9%+2.6pp41.1%+3.5pp46.2%+5.5pp
Operating Margin4.9%+2.2pp10.4%+7.6pp5.4%+9.8pp0.1%-3.9pp2.6%+0.3pp2.8%+1.6pp-4.3%+4.6pp4.0%+13.1pp
Net Margin3.6%+1.8pp7.8%+5.8pp3.7%+6.3pp-0.7%-5.8pp1.8%-1.3pp1.9%+0.6pp-2.6%+3.8pp5.2%+10.7pp
Return on Equity0.8%+0.4pp1.9%+1.4pp0.9%+1.5pp-0.2%-1.4pp0.4%-0.3pp0.4%+0.1pp-0.6%+0.8pp1.3%+2.5pp
Return on Assets0.5%+0.3pp1.2%+1.0pp0.6%+0.9pp-0.1%-0.9pp0.3%-0.1pp0.3%+0.1pp-0.3%+0.4pp0.8%+1.4pp
Current Ratio1.66+0.2x1.64+0.2x1.50+0.1x1.43+0.1x1.44+0.4x1.42-1.0x1.38-1.0x1.37-1.2x
Debt-to-Equity0.130.0x0.130.0x0.130.0x0.140.0x0.140.13-0.3x0.13-0.3x0.13-0.3x
Liabilities-to-Equity0.560.0x0.55-0.2x0.59-0.1x0.60-0.1x0.60-0.3x0.70-0.2x0.71-0.2x0.71-0.2x
Asset Turnover0.150.0x0.160.0x0.150.0x0.160.0x0.160.0x0.140.0x0.130.0x0.140.0x
FCF Margin7.0%+1.1pp19.0%+8.4pp13.6%+8.1pp7.2%-8.2pp6.0%+1.0pp10.7%-7.1pp5.5%-11.2pp15.4%+4.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Omnicell Inc OMCL FY2025 $1.2B $2.1M 0.2% $1.5B 46/100
Teladoc Health, Inc. TDOC FY2025 $2.5B -$200.3M -7.9% $1.4B 41/100
Certara, Inc. CERT FY2025 $418.8M -$1.6M -0.4% $1.6B 53/100
GoodRx Holdings, Inc. GDRX FY2025 $796.9M $30.4M 3.8% $1.0B 57/100
Omada Health, Inc. OMDA FY2025 $260.2M -$12.8M -4.9% $775.5M 55/100
HealthStream Inc HSTM FY2025 $304.1M $18.3M 6.0% $802.8M 53/100

Frequently Asked Questions

Omnicell Inc (OMCL) reported $1.2B in total revenue for fiscal year 2025. This represents a 6.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Omnicell Inc (OMCL) revenue grew by 6.5% year-over-year, from $1.1B to $1.2B in fiscal year 2025.

Yes, Omnicell Inc (OMCL) reported a net income of $44.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $2.1M, with a net profit margin of 0.2%.

Omnicell Inc (OMCL) reported diluted earnings per share of $0.04 for fiscal year 2025. This represents a -85.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Omnicell Inc (OMCL) had EBITDA of $84.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Omnicell Inc (OMCL) had $196.5M in cash and equivalents against $167.6M in long-term debt.

Omnicell Inc (OMCL) had a gross margin of 42.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Omnicell Inc (OMCL) had an operating margin of 0.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Omnicell Inc (OMCL) had a net profit margin of 0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Omnicell Inc (OMCL) has a return on equity of 0.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Omnicell Inc (OMCL) generated $86.9M in free cash flow during fiscal year 2025. This represents a -42.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Omnicell Inc (OMCL) generated $127.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Omnicell Inc (OMCL) had $2.0B in total assets as of fiscal year 2025, including both current and long-term assets.

Omnicell Inc (OMCL) invested $40.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Omnicell Inc (OMCL) invested $88.7M in research and development during fiscal year 2025.

Yes, Omnicell Inc (OMCL) spent $77.6M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Omnicell Inc (OMCL) had 45M shares outstanding as of fiscal year 2025.

Omnicell Inc (OMCL) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.

Omnicell Inc (OMCL) had a debt-to-equity ratio of 0.14 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Omnicell Inc (OMCL) had a liabilities-to-equity ratio of 0.60 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Omnicell Inc (OMCL) had a return on assets of 0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Omnicell Inc (OMCL) trades at 34.2x earnings, its market capitalization divided by $44.7M net income, trailing 12 months to September 30, 2026. The market capitalization is $1.5B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Omnicell Inc (OMCL) trades at 1.2x sales, its market capitalization divided by $1.2B revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.5B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Omnicell Inc (OMCL) has an Altman Z-Score of 2.24, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Omnicell Inc (OMCL) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Omnicell Inc (OMCL) reported $2.1M of net income while generating $127.3M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Omnicell Inc (OMCL) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top